Clinical Trial Update: A Study to Learn More About the Change in the Blood Levels of Transthyretin When Participants With Transthyretin Amyloidosis With Cardiomyopathy Switch From Tafamidis to Acoramidis [Phase 4]

View source ↗

Summary

This Phase 4 study sponsored by Bayer investigates changes in blood transthyretin levels when patients with transthyretin amyloid cardiomyopathy switch from taf…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Acoramidis (acoramidis)
• Tafamidis (tafamidis)

Snippet

Sponsor: Bayer | Conditions: Transthyretin Amyloid Cardiomyopathy | Phase 4 | Status: RECRUITING